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Abstract
Background: A substantial proportion of all pheochromocytomas is currently detected during the evaluation of an 
adrenal incidentaloma. Recently, it has been suggested that biochemical testing to rule out pheochromocytoma is 
unnecessary in case of an adrenal incidentaloma with an unenhanced attenuation value ≤10 Hounsfield Units (HU) at 
computed tomography (CT).
Objectives: We aimed to determine the sensitivity of the 10 HU threshold value to exclude a pheochromocytoma.
Methods: Retrospective multicenter study with systematic reassessment of preoperative unenhanced CT scans 
performed in patients in whom a histopathologically proven pheochromocytoma had been diagnosed. Unenhanced 
attenuation values were determined independently by two experienced radiologists. Sensitivity of the 10 HU threshold 
was calculated, and interobserver consistency was assessed using the intraclass correlation coefficient (ICC).
Results: 214 patients were identified harboring a total number of 222 pheochromocytomas. Maximum tumor 
diameter was 51 (39–74) mm. The mean attenuation value within the region of interest was 36 ± 10 HU. Only one 
pheochromocytoma demonstrated an attenuation value ≤10 HU, resulting in a sensitivity of 99.6% (95% CI:  
97.5–99.9). ICC was 0.81 (95% CI: 0.75–0.86) with a standard error of measurement of 7.3 HU between observers.
Conclusion: The likelihood of a pheochromocytoma with an unenhanced attenuation value ≤10 HU on CT is very low. 
The interobserver consistency in attenuation measurement is excellent. Our study supports the recommendation that 
in patients with an adrenal incidentaloma biochemical testing for ruling out pheochromocytoma is only indicated in 
adrenal tumors with an unenhanced attenuation value >10 HU.
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Introduction
Pheochromocytomas are rare neuroendocrine tumors 
arising from chromaffin tissue in the adrenal medulla 
(1). Timely diagnosis is crucial because patients are at 
increased risk for serious cardiovascular complications due 
to uncontrolled catecholamine hypersecretion (2, 3). In 
general, the presence of a pheochromocytoma is suspected 
in case of typical signs and symptoms such as paroxysmal 
headaches, palpitations, sweating and hypertension (4). 
The diagnosis of a pheochromocytoma is biochemically 
established by demonstration of elevated plasma or 
urinary levels of metanephrines, the O-methylated 
metabolites of catecholamines. However, a substantial 
proportion of patients with pheochromocytoma is either 
asymptomatic or may present with less typical signs and 
symptoms (5, 6). In such cases, a pheochromocytoma 
may be detected following the hormonal evaluation 
of an adrenal incidentaloma, which is defined as an 
adrenal mass >1 cm discovered incidentally during 
imaging procedures performed for reasons unrelated 
to adrenal disease (7). The reported prevalence of 
pheochromocytoma in adrenal incidentaloma cohorts 
is approximately 5–7% (8, 9). Conversely, nearly 30% of 
all pheochromocytomas are currently being diagnosed 
through the evaluation of adrenal incidentalomas (10). 
In view of these prevalence data, and the premise that a 
diagnosis of pheochromocytoma should not be missed, 
determination of metanephrines is recommended by the 
majority of guidelines on the management of adrenal 
incidentalomas (7, 9).
It has been suggested, however, that the likelihood of 
a pheochromocytoma is extremely low when the adrenal 
tumor demonstrates an unenhanced CT attenuation 
value ≤10 Hounsfield Units (HU). If this assumption 
would indeed be true, then expensive measurement 
of metanephrines could be reserved for adrenal 
incidentalomas with an unenhanced attenuation value 
above this threshold (11, 12, 13). In agreement with these 
observations, the recent guideline issued by the European 
Society of Endocrinology/European Network for the 
Study of Adrenal Tumors (ESE/ENSAT) states that it seems 
reasonable to avoid measuring metanephrines in case of an 
adrenal incidentaloma with an unenhanced attenuation 
value ≤10 HU (9). The quality of evidence behind this 
recommendation is very low, as only a few small-sized 
studies are available on this subject. Moreover, there are 
several reports describing pheochromocytomas with an 
unenhanced attenuation value ≤10 HU, suggesting that 
the sensitivity of this cut-off point might be suboptimal 
for application in clinical practice (14, 15).
We therefore aimed to systematically evaluate the 
characteristics of pheochromocytoma at unenhanced 
CT scan in a large-sized study in order to determine 
the diagnostic value of this cut-off value to exclude the 
presence of a pheochromocytoma.
Subjects and methods
Patients with histologically proven pheochromocytoma 
diagnosed between the year 2000 and 2017 were 
identified in six university medical centers and one non-
university teaching hospital in The Netherlands. Patients 
were considered eligible if the original preoperative 
unenhanced CT scan images of the adrenal glands were 
available for analysis. Recurrent or residual tumors were 
excluded. This retrospective study has been exempted 
from review and approval by the medical research and 
ethics committee of the University of Groningen, The 
Netherlands, according to the Dutch Medical Research 
Involving Human Subjects Act.
Clinical and biochemical data were extracted from 
the medical records and were anonymized before further 
analysis. Selected CT scans were reviewed independently 
by two experienced radiologists (T K and C H) using a 
standardized protocol. The radiologists were not blinded 
for the diagnosis of pheochromocytoma. Scanning 
acquisition and reconstruction parameters were extracted 
and the image quality was graded sufficient or insufficient 
for further analysis. The presence of movement or beam 
artifacts that interfered with attenuation measurement, 
incomplete visualization of the tumor and slice thickness 
>5 mm were considered as factors rendering the image 
quality insufficient. A two-dimensional region of interest 
(ROI) was drawn in the transversal plane by each 
radiologist avoiding the edges of the tumor and areas 
containing necrosis, calcifications and cystic formations. 
The radiologists had also access to the post-contrast series 
in case these were performed, which enabled more precise 
drawing of the ROI. The mean attenuation value, standard 
deviation of the attenuation value and ROI size were 
determined. In order to limit interobserver variability, a 
volume of interest (VOI) encapsulating the whole tumor 
was generated using a workstation (Syngo.via (version 
VB10B_HF06) Siemens Healthineers, Erlangen, Germany), 
which automatically determined the borders of the tumor. 
In a second step, these borders were visually checked and, 
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if needed, manually corrected. The software subsequently 
calculated the volume in which the mean attenuation 
value and the standard deviation of the attenuation value 
were determined. This enabled precise determination of 
the tumor volume even in case of an irregular shaped 
adrenal lesion. The standard deviation of each volumetric 
attenuation value was used as a measure of heterogeneity 
of the tumor. The amount of necrosis was estimated, and 
the presence of fine or coarse calcifications was graded.
The primary objective of this study was to determine 
the sensitivity of the 10 HU cut-off value to demonstrate 
or exclude the presence of a pheochromocytoma. 
Sensitivity was calculated as a percentage with 95% 
confidence intervals. As secondary objective of this study, 
we determined concordance between radiologists with 
respect to classification of the pheochromocytoma (i.e. 
attenuation ≤ or >10 HU) using Cohen’s Kappa coefficient. 
Consistency of attenuation measurements between 
radiologists was assessed using the intraclass correlation 
coefficient (ICC) and a standard error of measurement. 
Consistency between the volumetric measurement and 
transversal measurement was assessed with ICC. Another, 
secondary objective of this study was to determine 
potential relationships between the attenuation value, 
presence of calcifications, tumor necrosis tumor 
heterogeneity and acquisition and reconstruction 
parameters using Pearson’s or Spearman correlations 
coefficients were appropriate. Kruskal–Wallis and Mann–
Whitney tests were used to assess the relationship 
between attenuation value and categorical data where 
appropriate. The difference between volumetric and 
transversal attenuation measurement was calculated as a 
marker of selection bias in the ROI placement. Plasma and 
urinary metanephrines were calculated as ratios of the 
upper reference limit maintained by each laboratory and 
the biochemical phenotype was determined as previously 
described (16).
Data are represented as mean ± standard deviation 
(s.d.) or median (interquartile range) where appropriate. 
Statistical analyses were performed using SPSS, version 
23.0 for Windows (IBM Corporation). A two-sided P value 
<0.05 was considered significant.
Results
We initially identified 224 eligible patients with 
pheochromocytoma from whom a preoperative 
unenhanced CT scan was available. After review, 10 cases 
were excluded since the pheochromocytoma was not fully 
imaged in nine cases and the image quality was insufficient 
in one case. Therefore, 214 patients harboring a total of 
222 histologically confirmed pheochromocytomas were 
included into the final analysis. The mean age of patients 
was 53 ± 15 years, 60% were female and the biochemical 
phenotype was predominantly adrenergic (Table  1). In 
32% of cases, the pheochromocytoma was diagnosed 
during the evaluation of an adrenal incidentaloma. 
Acquisition and reconstruction characteristics are shown 
in Table 2. In 89% of CT scans, tube potential was set at 
120 kilovolt (kV) and in 85% of cases additional post-
contrast series were available.
The maximum tumor diameter in any plane was 
51 (39–74) mm and median tumor volume was 31 
(13–92) cm3. Mean unenhanced attenuation value within 
the ROI placed by each radiologist was 36 ± 9 HU and 
37 ± 9 HU for observer 1 and observer 2, respectively 
Table 1 Characteristics of 214 study subjects with a 
pheochromocytoma. Data are represented as mean ± s.d., 
median (IQR) or percentages.
Age (years) 53 ± 15
Sex (m/f) 40%/60%
BMI (kg/m2) 54.4 (21.8–27.9)
PCC localization (left/right/bilateral) 47%/49%/4%
Plasma MN (ratio of URL) 3.9 (1.1–14.3)
Plasma NMN (ratio of URL) 7.9 (2.3–18.8)
Urinary MN (ratio of URL) 4.1 (1.0–14.5)
Urinary NMN (ratio of URL) 3.6 (1.7–7.7)
Biochemical phenotype (A/NA) 66%/34%
A, adrenergic; BMI, body mass index; MN, metanephrine; NA, 
noradrenergic; NMN, normetanephrine; PCC, pheochromocytoma; URL, 
upper reference limit.
Table 2 Acquisition and reconstruction parameters of 214 CT 
scans. Data are represented as percentage or median (IQR).
Parameters Values
Slices
  16 17%
  64 21%
  320 14%
  Other 28%
  Unknown 20%
Slice thickness (mm) 3.0 (2.0–3.2)
Slice increment (mm) 2.0 (1.5–3.0)
Tube potential (kV)
  <120 7%
  120 89%
  >120 4%
Reconstruction kernel
  Soft 39%
  Medium 56%
  Unknown 5%
kV, kilovolt.
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(Table  3). The ICC was 0.81 (95% CI: 0.75–0.86) and 
standard error of measurement was 7.3 HU between 
observers. The unenhanced attenuation value of 221 
pheochromocytomas was classified >10 HU by both 
radiologists, whereas one pheochromocytoma was 
judged concordantly ≤10 HU. This resulted in perfect 
interobserver reliability: k = 1.00, P < 0.001. The sensitivity 
of the 10 HU cut-off for identifying a pheochromocytoma 
was 99.6% (95% CI: 97.5–99.9; Figs 1 and 2).
Mean attenuation value in the VOI was 32 ± 9 HU. 
ICC was 0.75 (95% CI: 0.24–0.89) and standard error 
of measurement was 8.4 HU between the volumetric 
attenuation value and both measurements in the 
transversal plane. The difference between volumetric 
and transversal attenuation measurements was positively 
associated with tumor heterogeneity (standard deviation 
of the VOI attenuation value, Rs 0.23, P = 0.001) as well as, 
with the presence of necrosis (Rs 0.32, P < 0.001), but not 
with tumor volume (Rs 0.06, P = 0.399).
Interrater reliability between radiologists for scoring 
calcifications and necrosis was k = 0.56 and k = 0.54, 
respectively (P < 0.001 for both). The mean attenuation 
value in the transversal plane was not significantly 
associated with tumor volume, presence of calcifications, 
tube potential or tumor heterogeneity (data not shown). 
The mean attenuation value in the transversal plane was 
lower in tumors containing more than 50% necrosis 
(mean attenuation 37 ± 9, 38 ± 6, 38 ± 7 and 33 ± 7 HU for 
0, 1–10, 11–50 and >50% necrosis respectively, P = 0.029).
The single patient with an unenhanced attenuation 
value ≤10 HU was found to have Cushing’s syndrome 
caused by ectopic ACTH secretion from a left-sided 
pheochromocytoma. The diagnosis of pheochromocytoma 
was not considered before surgery, but was established 
by pathological examination of the resected adrenal 
gland, demonstrating a 3.5 cm large tumor consisting 
of cell nests with eosinophilic cytoplasm, with positive 
immunohistochemical staining for chromogranine, 
synaptophysine, S-100 and ACTH. Preoperative 
Table 3 Tumor characteristics and attenuation values of 222 pheochromocytomas. Data are represented as mean ± s.d., median 
(IQR) or percentages.
Tumor characteristics Values Observer 1 Observer 2 Volumetric
Diameter transversal plane (mm) 43 (33–64)
Orthogonal diameter (mm) 36 (25–50)
Maximum diameter (mm) 51 (39–74)
Calcifications (%)
  None 93
  Fine 3
  Course 4
Necrosis (%)
  0 51
  ≤10 10
  11–50 21
  >50 18
Region of interest (cm2)* 4.8 (2.7–8.3) 2.9 (1.6–5.2) 31 (13–92)
Mean attenuation value (HU) 36 ± 9 37 ± 9 32 ± 9
s.d. attenuation value (HU) 18 ± 7 18 ± 8 24 ± 9
*The region of interest for the volumetric measurement is expressed as cm3.
HU, Hounsfield Units.
Figure 1
Bland–Altman plot of 222 pheochromocytoma showing the 
mean value of attenuation measurements by two radiologists 
from a single patient (X-axis) plotted against the difference 
between the same two results (Y-axis). The solid horizontal 
line represents the mean difference of all measurements with 
corresponding 95% limits of agreement represented as the 
dotted lines.
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urinary free cortisol excretion was 13  000 nmol/24 h. 
The unenhanced attenuation value measured by both 
radiologists was −4 HU and the VOI attenuation value 
was −15 HU. Remarkably, the standard deviation of 
the attenuation value of this tumor represented the 
highest value of the entire study population (i.e. 66 HU), 
despite the absence of necrosis, cystic parts or 
calcifications (Fig. 3).
Discussion
In this large retrospective multicenter study, we show that 
the finding of an unenhanced attenuation value ≤10 HU 
in an adrenal gland tumor has a high diagnostic value of 
99.6% to exclude the presence of a pheochromocytoma. 
Moreover, the applicability of this method is underlined 
by the excellent interobserver agreement.
Over the past two decades, there has been a rapid 
increase in the utilization of various imaging techniques, 
which has led to a marked rise in the detection rate of 
adrenal incidentalomas. Radiological studies report a 
frequency varying from 3% to 10%, with the highest 
rates among the elderly (9, 17, 18, 19). The detection of 
an adrenal incidentaloma should be followed by further 
analysis in order to evaluate whether the lesion is hormonal 
active or not and whether the adrenal tumor is benign or 
malignant. For this purpose, several algorithms have been 
developed (7, 9, 20). One of the common denominators 
in all these algorithms is the recommendation to measure 
metanephrines in plasma or urine in order to exclude 
the presence of a pheochromocytoma. However, the 
recently issued ESE/ENSAT guideline has suggested that 
determination of metanephrines might be obviated in 
case of an adrenal incidentaloma with an unenhanced CT 
attenuation value ≤10 HU (9). This recommendation was 
based on small-sized studies predominantly describing 
pheochromocytomas with an unenhanced attenuation 
value >10 HU (21, 22). In agreement with these earlier 
reports, we demonstrate that pheochromocytomas with 
low unenhanced attenuation values are a very infrequent 
phenomenon.
Biochemical tests for pheochromocytoma have an 
excellent negative predictive value of 0.99 (23). However, 
the specificity depends quite strongly on preanalytical 
conditions, such as the use of certain drugs (e.g. tricyclic 
antidepressants, dopamine D2 receptor antagonists) 
and the requirement of a correctly collected 24-h 
urine or blood sampling after at least 20 min of supine 
rest for measurement of metanephrines in urine or 
plasma, respectively (24). In addition, determination of 
metanephrines is rather expensive. As it is not always 
feasible to create optimal preanalytical conditions the 
rate of false-positive measurements might be increased, 
subsequently resulting in more diagnostic testing to rule 
out pheochromocytoma at higher costs (25). Moreover, 
almost 70% of adrenal incidentalomas demonstrate 
attenuation values ≤10 HU, illustrating the large proportion 
of patients that might benefit from using the attenuation 
threshold in order to determine which patients need 
biochemical screening as second-line testing to rule out 
pheochromocytoma (26). Notably, approximately 3500 
patients with adrenal incidentaloma and attenuation 
value ≤10 HU would need to be biochemically screened 
in order to diagnose one case of pheochromocytoma, 
Figure 2
Cumulative distribution in percentage (Y-axis) displayed for 
the mean attenuation value (X-axis) for 222 
pheochromocytomas on the left. On the right side, a 
magnification of the lower range of attenuation values 
including the intersection with the 10 HU cut-off value.
Figure 3
Left-sided pheochromocytoma with ectopic ACTH production 
demonstrating an unenhanced attenuation value of −4 HU.
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assuming a 5% prevalence of pheochromocytoma in the 
adrenal incidentaloma population, 70% frequency of 
attenuation ≤10 HU and a false-negative rate of 0.4% of 
radiological classification as determined in the present 
study. We cannot exclude, however, the possibility that 
under certain clinical circumstances determination of 
metanephrines might still be indicated in case of an 
adrenal mass with a attenuation <10 HU, e.g. in a patient 
with symptoms suggestive of a pheochromocytoma or 
when biopsy or adrenalectomy is considered.
The single patient with a false-negative CT scan had 
an unusual clinical picture of Cushing’s syndrome due to 
ectopic ACTH production by a pheochromocytoma. In 
this case, the mean attenuation value might have been 
decreased as a result of the higher cholesterol content 
associated with the profound hypersecretion of cortisol as 
is also supported by the extremely high standard deviation 
of the attenuation value.
Our data further illustrate that clinical applicability 
of this measurement in daily practice is very reliable if 
basic rules of ROI drawing are taken into account (27). 
This is underlined by good interobserver consistency and 
excellent concordance between radiologists. Selective 
ROI placement was shown to be especially valuable in 
heterogeneous tumors with more necrosis. It has been 
shown that acquisition and reconstruction parameters 
of CT scans, such as tube potential and scanner type, 
can induce small changes in attenuation values and a 
lack of uniformity in these settings might be considered 
a shortcoming of the current study (28). For example, a 
significant proportion of adrenal incidentalomas was 
reclassified over time when using the 10 HU cut-off value 
due to variability between CT scanners and observer 
(29). However, the magnitude of this variability is very 
low and our data show that only a small proportion of 
pheochromocytomas demonstrates an attenuation value 
close to 10 HU. This suggests that differences in acquisition 
and reconstruction parameters or interobserver variability 
are unlikely to affect the radiologic classification of these 
adrenal tumors (28).
The major strengths of the current study are the 
systematic reassessment by two independent radiologists 
performing attenuation measurements in accordance 
with daily practice in a relatively large number of 
pheochromocytomas. A limitation of our study is the 
possibility of confirmation bias due to the non-blinded 
design or incorporation bias as CT is part of routine 
diagnostic work-up in case of a pheochromocytoma. Also, 
its retrospective design, and the fact that we were not able 
to determine the specificity of the HU threshold value 
since no control group was included might be considered 
as a limitation. It should be noted, however, that the 
specificity of the 10 HU cut-off value is known to be very 
low for diagnosing a pheochromocytoma (30).
In conclusion, the likelihood that an adrenal 
incidentaloma with an unenhanced CT attenuation value 
≤10 HU represents a pheochromocytoma is very low. Our 
results do not support the widespread clinical practice 
to determine metanephrines in every patient with an 
adrenal incidentaloma.
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